• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后中和抗体反应的纵向动力学。

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

机构信息

Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

出版信息

Clin Infect Dis. 2021 Aug 2;73(3):e531-e539. doi: 10.1093/cid/ciaa1143.

DOI:10.1093/cid/ciaa1143
PMID:32745196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7454328/
Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing antibodies (NAbs) in patients with COVID-19.

METHODS

Blood samples (n = 173) were collected from 30 patients with COVID-19 over a 3-month period after symptom onset and analyzed for SARS-CoV-2-specific NAbs using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines.

RESULTS

SARS-CoV-2-specific NAb titers were low for the first 7-10 days after symptom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 days (interquartile range [IQR], 24-59 days) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR, 19.6-42.4%). NAb titers increased over time in parallel with the rise in immunoglobulin G (IgG) antibody levels, correlating well at week 3 (r = 0.41, P < .05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including stem cell factor (SCF), TNF-related apoptosis-inducing ligand (TRAIL), and macrophage colony-stimulating factor (M-CSF).

CONCLUSIONS

These data provide useful information regarding dynamic changes in NAbs in patients with COVID-19 during the acute and convalescent phases.

摘要

背景

2019 年冠状病毒病（COVID-19）是一种全球性大流行病，目前尚无针对该疾病的许可疫苗或特定抗病毒药物。对于 COVID-19 患者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）特异性中和抗体（NAb）的纵向动态变化知之甚少。

方法

采集了 30 例 COVID-19 患者发病后 3 个月内的 173 份血样，使用慢病毒假型测定法分析 SARS-CoV-2 特异性 NAb，同时分析 IgG 和促炎细胞因子的水平。

结果

在症状出现后的第 7-10 天，SARS-CoV-2 特异性 NAb 滴度较低，2-3 周后增加。NAb 的中位峰值时间为症状出现后 33 天（四分位距[IQR]，24-59 天）。93.3%（28/30）的患者在 3 个月的研究期间，NAb 滴度逐渐下降，中位数下降 34.8%（IQR，19.6-42.4%）。NAb 滴度随时间的增加而逐渐增加，与 IgG 抗体水平的升高平行，在第 3 周相关性良好（r = 0.41，P <.05）。NAb 滴度与血浆促炎细胞因子水平也呈显著正相关，包括干细胞因子（SCF）、肿瘤坏死因子相关凋亡诱导配体（TRAIL）和巨噬细胞集落刺激因子（M-CSF）。

结论

这些数据为 COVID-19 患者在急性和恢复期 NAb 的动态变化提供了有用的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/030f9a107e81/ciaa1143f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/4875cb7b8c3a/ciaa1143f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/5dc4f7c5607a/ciaa1143f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/93782102431b/ciaa1143f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/b721afba834f/ciaa1143f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/030f9a107e81/ciaa1143f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/4875cb7b8c3a/ciaa1143f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/5dc4f7c5607a/ciaa1143f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/93782102431b/ciaa1143f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/b721afba834f/ciaa1143f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3b3/8326556/030f9a107e81/ciaa1143f0005.jpg

相似文献

1
Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后中和抗体反应的纵向动力学。
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539. doi: 10.1093/cid/ciaa1143.
2
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.评估中国上海轻症 COVID-19 康复患者临床特征与中和抗体水平的相关性。
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362. doi: 10.1001/jamainternmed.2020.4616.
3
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.COVID-19 患者症状出现后七个月内 SARS-CoV-2 特异性和中和抗体的动力学。
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. doi: 10.1128/Spectrum.00590-21. Epub 2021 Sep 22.
4
[Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].[新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2病毒脱落情况及中和抗体水平]
Mikrobiyol Bul. 2022 Jul;56(3):416-431. doi: 10.5578/mb.20229704.
5
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
6
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.新墨西哥州恢复期血浆和接受者中严重急性呼吸综合征冠状病毒 2 中和抗体滴度：2019 年冠状病毒病患者的开放性治疗研究。
J Infect Dis. 2020 Oct 13;222(10):1620-1628. doi: 10.1093/infdis/jiaa505.
7
Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.五种市售血清学检测方法检测 SARS-CoV-2 抗体的性能比较及识别高中和抗体滴度个体。
J Clin Microbiol. 2021 Jan 21;59(2). doi: 10.1128/JCM.02257-20.
8
Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test.一种用于检测中和抗体的新型冠状病毒2快速检测试剂盒作为即时检测监测测试的诊断价值
Microbiol Spectr. 2022 Apr 27;10(2):e0099321. doi: 10.1128/spectrum.00993-21. Epub 2022 Mar 7.
9
Antibody Responses to SARS-CoV-2 in Children With COVID-19.儿童 COVID-19 患者对 SARS-CoV-2 的抗体反应。
J Pediatric Infect Dis Soc. 2022 Jun 22;11(6):267-273. doi: 10.1093/jpids/piac012.
10
Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.康复的 COVID-19 患者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白特异性和中和抗体的长期持久性。
PLoS One. 2022 Apr 21;17(4):e0267102. doi: 10.1371/journal.pone.0267102. eCollection 2022.

引用本文的文献

1
BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.卡介苗免疫通过单核细胞胞葬作用和肺部中性粒细胞募集减轻猕猴体内的新冠病毒复制。
JCI Insight. 2025 Aug 8;10(15). doi: 10.1172/jci.insight.194633.
2
A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population.对新墨西哥州人群中SARS-CoV-2感染抗体反应的纵向评估。
PLoS One. 2025 Jul 8;20(7):e0327698. doi: 10.1371/journal.pone.0327698. eCollection 2025.
3
A tentative exploration for the association between influenza virus infection and SARS-CoV-2 infection in Shihezi, China: A test-negative study.

本文引用的文献

1
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.恢复期血浆疗法治疗 COVID-19 患者：抗体检测方法评估及其与中和抗体水平的相关性。
Transfus Med. 2021 Jun;31(3):167-175. doi: 10.1111/tme.12746. Epub 2020 Dec 17.
2
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.SARS-CoV-2 血清阳性率及中和活性在供者和患者血液中的变化。
Nat Commun. 2020 Sep 17;11(1):4698. doi: 10.1038/s41467-020-18468-8.
3
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
中国石河子流感病毒感染与新型冠状病毒感染关联的初步探索：一项检测阴性研究
Infect Dis Model. 2024 Oct 9;10(1):201-206. doi: 10.1016/j.idm.2024.10.002. eCollection 2025 Mar.
4
SARS-CoV-2 virus: Vaccines in development.严重急性呼吸综合征冠状病毒2：正在研发的疫苗
Fundam Res. 2021 Mar;1(2):131-138. doi: 10.1016/j.fmre.2021.01.009. Epub 2021 Jan 22.
5
Realization of humoral immunity against SARS-CoV-2 infections.实现针对新型冠状病毒肺炎感染的体液免疫
Fundam Res. 2021 Mar;1(2):186-188. doi: 10.1016/j.fmre.2021.01.008. Epub 2021 Jan 22.
6
The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.疫苗接种频率对COVID-19公共卫生结果的影响：基于模型的分析。
Vaccines (Basel). 2025 Mar 30;13(4):368. doi: 10.3390/vaccines13040368.
7
Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients.科兴疫苗接种者中针对新冠病毒变异株的RBD-ACE2阻断抗体与结合抗体之间的时间相关性及其在新冠患者中的持久性
Sci Rep. 2025 May 6;15(1):15831. doi: 10.1038/s41598-025-98627-3.
8
Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence.海德堡大学医院中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的流行情况及其与SARS-CoV-2发病率的相关性。
Heliyon. 2024 Nov 13;10(22):e40282. doi: 10.1016/j.heliyon.2024.e40282. eCollection 2024 Nov 30.
9
Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023.2022 年至 2023 年期间，在中国广东省观察到 SARS-CoV-2 奥密克戎 BA.5 和 XBB.1.9 流行后的免疫逃逸现象。
Virol J. 2024 Nov 20;21(1):298. doi: 10.1186/s12985-024-02573-x.
10
Hybrid response to SARS-CoV-2 and C after an OMV-adjuvanted immunization in mice and their offspring.在小鼠及其后代中，用 OMV 佐剂免疫后对 SARS-CoV-2 和 C 的混合反应。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2346963. doi: 10.1080/21645515.2024.2346963. Epub 2024 May 15.
mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
4
Kinetics of viral load and antibody response in relation to COVID-19 severity.病毒载量和抗体反应动力学与 COVID-19 严重程度的关系。
J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759.
5
The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.严重急性呼吸综合征冠状病毒2的核衣壳蛋白：疫苗开发的一个靶点
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00647-20.
6
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.一种人源中和抗体靶向 SARS-CoV-2 的受体结合位点。
Nature. 2020 Aug;584(7819):120-124. doi: 10.1038/s41586-020-2381-y. Epub 2020 May 26.
7
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.SARS-CoV-2 感染可使恒河猴免受再次感染。
Science. 2020 Aug 14;369(6505):812-817. doi: 10.1126/science.abc4776. Epub 2020 May 20.
8
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.高通量单细胞测序鉴定恢复期患者 B 细胞中的 SARS-CoV-2 强效中和抗体。
Cell. 2020 Jul 9;182(1):73-84.e16. doi: 10.1016/j.cell.2020.05.025. Epub 2020 May 18.
9
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.一对非竞争的人源中和抗体可阻断 COVID-19 病毒与其受体 ACE2 的结合。
Science. 2020 Jun 12;368(6496):1274-1278. doi: 10.1126/science.abc2241. Epub 2020 May 13.
10
COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives.新型冠状病毒肺炎：流行病学、进化与跨学科视角。
Trends Mol Med. 2020 May;26(5):483-495. doi: 10.1016/j.molmed.2020.02.008. Epub 2020 Mar 21.